Tymlos, Eladynos(abaloparatide)
Eladynos, Tymlos (abaloparatide) is a protein pharmaceutical. Abaloparatide was first approved as Tymlos on 2017-04-28. It is used to treat pasteurellaceae, postmenopausal osteoporosis, and postmenopausal osteoporosis in the USA. It has been approved in Europe to treat osteoporosis and postmenopausal osteoporosis. The pharmaceutical is active against parathyroid hormone/parathyroid hormone-related peptide receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| musculoskeletal diseases | D009140 |
| nutritional and metabolic diseases | D009750 |
Trade Name
FDA
EMA
Tymlos
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Abaloparatide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TYMLOS | Radius Health | N-208743 RX | 2017-04-28 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| tymlos | New Drug Application | 2025-04-04 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| postmenopausal osteoporosis | EFO_0003854 | D015663 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
ABALOPARATIDE, TYMLOS, RADIUS | |||
| 2025-12-19 | I-907 | ||
| 2024-09-20 | M-270 | ||
HCPCS
No data
Clinical
Clinical Trials
23 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | 3 | 2 | 7 | 2 | 2 | 16 |
| Postmenopausal osteoporosis | D015663 | EFO_0003854 | — | 1 | 1 | 4 | 1 | 2 | 9 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | 2 | — | 1 | — | 3 |
| Femoral fractures | D005264 | — | S72 | — | — | — | 1 | — | 1 |
| Distal femoral fractures | D000092524 | — | — | — | — | — | 1 | — | 1 |
| Replacement arthroplasty knee | D019645 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteoporotic fractures | D058866 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Intervertebral disc degeneration | D055959 | — | — | — | 1 | — | — | — | 1 |
| Hip fractures | D006620 | EFO_0003964 | S72.00 | — | 1 | — | — | — | 1 |
| Spinal fusion | D013123 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 1 | — | — | — | — | 1 |
| Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | 1 | — | — | — | — | 1 |
| Preleukemia | D011289 | — | — | 1 | — | — | — | — | 1 |
| Syndrome | D013577 | — | — | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Metabolic bone diseases | D001851 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Abaloparatide |
| INN | abaloparatide |
| Description | Abaloparatide (brand name Tymlos) is a parathyroid hormone-related protein (PTHrP) analog drug used to treat osteoporosis. Like the related drug teriparatide, and unlike bisphosphonates, it is an anabolic (i.e., bone growing) agent.
|
| Classification | Protein |
| Drug class | peptides: parathyroid hormone related peptide |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 247062-33-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3301581 |
| ChEBI ID | — |
| PubChem CID | 76943386 |
| DrugBank | DB05084 |
| UNII ID | AVK0I6HY2U (ChemIDplus, GSRS) |
Target
Agency Approved
PTH1R
PTH1R
Organism
Homo sapiens
Gene name
PTH1R
Gene synonyms
PTHR, PTHR1
NCBI Gene ID
Protein name
parathyroid hormone/parathyroid hormone-related peptide receptor
Protein synonyms
Parathyroid hormone 1 receptor, parathyroid hormone receptor 1, parathyroid hormone/parathyroid hormone-related protein receptor, PTH/PTHr receptor, PTH/PTHrP type I receptor, PTH1 receptor, seven transmembrane helix receptor
Uniprot ID
Mouse ortholog
Pth1r (19228)
parathyroid hormone/parathyroid hormone-related peptide receptor (Q80WU8)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,207 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
18,508 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use